UPM Pharmaceuticals will expand its existing manufacturing capacity with an OEB 4 processing room, a low humidity processing suite, and a dedicated Xcelodose production facility. The overall expansion will add 50% more manufacturing space for current production. UPM’s president, James Gregory, said, “To meet our client’s growing needs, UPM is making a major capital commitment to enhance client services. In response to an increasing number of requests for production of compounds with more string...